You are here

SGLT2 inhibitors for type 1 diabetes: clinical implications

Wednesday, 18 September 2019, 08:30 - 10:00, Joslin Hall

Chair: P. Narendran, UK

T.R. Pieber, AT: Unmet needs in the management of type 1 diabetes: implications for therapy with SGLT2is

R.J. McCrimmon, UK: Clinical trial data for SGLT2is in type 1 diabetes

T. Danne, DE: Safe use of SGLT2is in type 1 diabetes